Filing Flows › Industrials › Pacific Biosciences of California (PACB)

Pacific Biosciences of California (PACB) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Pacific Biosciences of California (PACB) Q3 2026 earnings results →

Q3 2026 Revenue up 6% year over year to $40.6M · 93¢ of every $1 of revenue lost · operating margin -91.2%

Pacific Biosciences of California made $40.6M in Q3 2026 (+6% Y/Y): Product revenue $34.0M, Service and other revenue $6.6M. Operating margin -91.2%, net loss $37.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.

Revenue$40.6M

Year over year+6%

Operating margin-91.2%

Net earnings−$37.8M

Operating cash flow−$37.6M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $40.6M in Q3 2026, up 6% year over year and up 4% from the previous quarter. Consumables revenue was the largest line at 51% of revenue. Instrument revenue added $1.9M year over year (up 16%), 88% of the total change. Consumables revenue declined 2%.

Gross margin was 33.2%, down 8.2 points from Q3 2025. Operating costs exceeded revenue by $37.0M, an operating margin of -91.2%. Operating expenses fell 8% while revenue rose 6%. The quarter ended with a net loss of $37.8M, narrower than the previous quarter's $44.7M loss.

Operating cash flow was −$37.6M. Non-cash charges added back $2.5M of depreciation and $8.5M of share-based compensation. Working capital and other items used $10.8M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$38.6M.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Nov 5, 2026	$40.6M	+6%	-91.2%	−$37.8M	−$37.6M
Q2 2026	10-Q	Aug 6, 2026	$39.0M	-2%	-114.4%	−$44.7M	−$35.6M
Q1 2026	10-Q	May 8, 2026	$37.2M	+0.1%	-22.5%	−$8.3M	−$44.7M
Q4 2025	10-K	Feb 25, 2026	$44.6M	+14%	-92.3%	−$40.4M	−$19.1M
Q3 2025	10-Q	Nov 6, 2025	$38.4M	-4%	-101.1%	−$38.0M	−$18.7M
Q2 2025	10-Q	Aug 7, 2025	$39.8M	+10%	-112.8%	−$41.9M	−$29.4M
Q1 2025	10-Q	May 12, 2025	$37.2M	-4%	n/m	−$426M	−$44.1M

Charts

Latest (Q3 2026): Y/Y +6%, Q/Q +4%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income −$37.8M, Operating cash flow −$37.6M.

+71.4% since FY2020: more shares outstanding (issuance, stock pay).

Laboratory Analytical Instruments; dot size is quarterly revenue; dashed lines are the industry's medians.